Emerging strategies for the improvement of chemotherapy in bladder cancer: Current knowledge and future perspectives

BACKGROUND: Chemotherapy is a first-line treatment for advanced and metastatic bladder cancer, but the unsatisfactory objective response rate to this treatment yields poor 5-year patient survival. Only PD-1/PD-L1-based immune checkpoint inhibitors, FGFR3 inhibitors and antibody-drug conjugates are a...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Sen, Chen, Xu, Lin, Tianxin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9263750/
https://www.ncbi.nlm.nih.gov/pubmed/35777908
http://dx.doi.org/10.1016/j.jare.2021.11.010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9263750/
https://www.ncbi.nlm.nih.gov/pubmed/35777908
http://dx.doi.org/10.1016/j.jare.2021.11.010

Ejemplares similares